---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020891"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:24:22.366064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance

## Summary
- Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.
- Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.
- Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.
- Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.
- Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq.

## SEC filing metadata
- accession: 0001493152-25-020891
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/0001493152-25-020891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020891
- JSON: https://secwatch.observer/filing/0001493152-25-020891.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.